Leerink Partners cuts AXSOME Therapeutics target price to $245 from $265
AXSM•Leerink Partners cut its target price for Axsome Therapeutics to $245 from $265.
Related News
Google Cloud, Balyasny Asset Management partner to deploy Gemini in financial research platform
GOOGL•
Service Properties Trust announces quarterly cash distribution of $0.05 a share
SVC•
Onar names Kelly Anderson interim CFO, Howard Palefsky to chair Audit Committee
ONAR•
Hyperfine to report Q3 2026 financial results, host conference call
HYPR•
Edgewise Therapeutics doses first patient in Phase 2 EDG-15400 HFpEF trial
EWTX•